Congress speakers OT 2020

The congress speakers will be:


Francesco qualified from University of Padua (Italy) with a DVM in 2006. He spent the next 4 years in small animal practice. In 2010, he started a residency program in Clinical Pathology at the University of Cambridge, which he finished in 2013 attaining both an ECVCP and FRCPath diploma. Francesco joined the Animal Health Trust in 2013 as Head of Clinical Pathology, and from September 2015 works for Battlab (LABOKLIN). Francesco has a special interest in lymphoproliferative disorders of dogs and cats and flow cytometry.
He is member of the cytology exam committee of the European College of Veterinary Clinical Pathology (ECVCP) and secretary of the same college. He is a regular speaker for BSAVA, UNISVET and ESAVS. He is author of several publications on peer-reviewed journals and of the cytology chapter of the BSAVA Manual of Veterinary Clinical Pathology (3ed). He is also editor of the books “Veterinary Cytology: Dog, Cat, Horse and Cow: Self-Assessment Color Review” for CRC press and the most recent Differential Diagnosis in Small Animal Cytology: The Skin and Subcutis” for CABI.

– LAURENT FINDJI    DMV MS MRCVS DiplECVS  European and RCVS Recognised Specialist in Small Animal Surgery

Laurent graduated from Paris’ vet school, the Ecole Nationale Vétérinaire d’Alfort, in France, and was subsequently assistant instructor in the anatomy department for a year. He then qualified for a 2-year surgical internship in the same school and later completed a Master of Science in Biology and Physiology of Circulation and Respiration, as well as a university degree in Experimental Surgery and Microsurgery.

He completed an ECVS residency at the Centre Hospitalier Vétérinaire Frégis, near Paris and became a diplomate of the European College of Veterinary Surgeons in 2008.

Laurent worked at VRCC Veterinary Referrals in Essex, from 2006 to 2014, where he was one of the full-time soft-tissue surgeons and directors. He joined Fitzpatrick Referrals in October 2014, where he currently is a senior consultant surgeon and director of the Oncology and Soft Tissue hospital. His fields of interest include oncologic, reconstructive and general soft tissue surgeries.

– PHILIP BERGMAN : DVM, MS, PhD, DACVIM (Oncology) Veterinary Specialist

Dr. Bergman is the Director of Clinical Studies for VCA.  He is an adjunct faculty member of the Memorial Sloan-Kettering Cancer Center and the principal veterinary investigator for the canine melanoma vaccine (Oncept®), which was fully licensed in 2009.  Prior to Dr. Bergman joining VCA, he served as the Chief Medical Officer for BrightHeart Veterinary Centers from 2007 to 2011; from 1999 – 2007 he was the head of the Donaldson-Atwood Cancer Center at AMC.  After finishing veterinary school from Colorado State in 1990, he was an intern at Kansas State (‘90-‘91) and returned to CSU for his medical oncology residency (‘91-‘94) and then completed a PhD Fellowship in human cancer biology from the M.D. Anderson Cancer Center in Houston (‘94-‘99).  He was previously Chair of the ACVIM Board of Regents and President of the Veterinary Cancer Society.

Prof Dr Ferry Ossendorp PhD


Full Professor Molecular Vaccine Biology


Area(s) of interest

– Regulation of CD4 and CD8 T cell immunity

– Antigen processing and dendritic cell biology

– Cancer immunotherapy



Ferry Ossendorp studied Biology and obtained his PhD degree in 1989 at the Netherlands Cancer Institute, University of Amsterdam. Postdoctoral research was carried out in the Immunology Division at the Netherlands Cancer Institute till 1992. Since 1993 started as a senior scientist in the department of Immunohematology and Blood transfusion in LUMC. Since 1996 he is scientific staff member of the department and group leader. He became Associate Professor in 2005 and Full Professor in 2010. Ferry Ossendorp has currently published 162 peer-reviewed publications and is inventor on five patents involving potentiation of cancer vaccines. Since 2013 he is Scientific board member of Dutch Cancer Foundation KWF.

The research of Ossendorp focuses on fundamental and translational tumor immunology. Immune therapeutic strategies in several animal models are studied, including T cell immunity, antigen processing and presentation, dendritic cell biology and the role of the tumor microenvironment. The role of T helper and regulatory cell types and the effects of several dendritic cell-modulating agents like Toll-like receptor ligands on the CD8 immune response are subjects of study. Combination therapies applying chemo- or photodynamic therapy and modulation of the tumor microenvironment with checkpoint blocking antibodies are studied in our preclinical models.

Dedicated design of molecular defined cancer vaccines which has resulted in clinical translation. Several antigen systems including model antigens, oncogenic viruses and neoantigens are studied. Optimization of vaccine delivery systems include dendritic cell targeting by biodegradable nanoparticles, Toll like receptor ligands and defined DNA vaccines. Peptide-based T cell vaccines conjugated to chemically well-defined TLR ligands have been in-house GMP produced and currently explored for immunotherapeutic treatment of cancer patients.